1. Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis
- Author
-
Papanicolaou, M, Parker, AL, Yam, M, Filipe, EC, Wu, SZ, Chitty, JL, Wyllie, K, Tran, E, Mok, E, Nadalini, A, Skhinas, JN, Lucas, MC, Herrmann, D, Nobis, M, Pereira, BA, Law, AMK, Castillo, L, Murphy, KJ, Zaratzian, A, Hastings, JF, Croucher, DR, Lim, E, Oliver, BG, Mora, FV, Parker, BL, Gallego-Ortega, D, Swarbrick, A, O'Toole, S, Timpson, P, Cox, TR, Papanicolaou, M, Parker, AL, Yam, M, Filipe, EC, Wu, SZ, Chitty, JL, Wyllie, K, Tran, E, Mok, E, Nadalini, A, Skhinas, JN, Lucas, MC, Herrmann, D, Nobis, M, Pereira, BA, Law, AMK, Castillo, L, Murphy, KJ, Zaratzian, A, Hastings, JF, Croucher, DR, Lim, E, Oliver, BG, Mora, FV, Parker, BL, Gallego-Ortega, D, Swarbrick, A, O'Toole, S, Timpson, P, and Cox, TR
- Abstract
The tumour stroma, and in particular the extracellular matrix (ECM), is a salient feature of solid tumours that plays a crucial role in shaping their progression. Many desmoplastic tumours including breast cancer involve the significant accumulation of type I collagen. However, recently it has become clear that the precise distribution and organisation of matrix molecules such as collagen I is equally as important in the tumour as their abundance. Cancer-associated fibroblasts (CAFs) coexist within breast cancer tissues and play both pro- and anti-tumourigenic roles through remodelling the ECM. Here, using temporal proteomic profiling of decellularized tumours, we interrogate the evolving matrisome during breast cancer progression. We identify 4 key matrisomal clusters, and pinpoint collagen type XII as a critical component that regulates collagen type I organisation. Through combining our proteomics with single-cell transcriptomics, and genetic manipulation models, we show how CAF-secreted collagen XII alters collagen I organisation to create a pro-invasive microenvironment supporting metastatic dissemination. Finally, we show in patient cohorts that collagen XII may represent an indicator of breast cancer patients at high risk of metastatic relapse.
- Published
- 2022